Cargando…
The Potential of the Cyclotide Scaffold for Drug Development
Cyclotides are a novel class of micro-proteins (≈30–40 residues long) with a unique topology containing a head-to-tail cyclized backbone structure further stabilized by three disulfide bonds that form a cystine knot. This unique molecular framework makes them exceptionally stable to physical, chemic...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631875/ https://www.ncbi.nlm.nih.gov/pubmed/31010257 http://dx.doi.org/10.3390/biomedicines7020031 |
_version_ | 1783435621026496512 |
---|---|
author | Camarero, Julio A. Campbell, Maria Jose |
author_facet | Camarero, Julio A. Campbell, Maria Jose |
author_sort | Camarero, Julio A. |
collection | PubMed |
description | Cyclotides are a novel class of micro-proteins (≈30–40 residues long) with a unique topology containing a head-to-tail cyclized backbone structure further stabilized by three disulfide bonds that form a cystine knot. This unique molecular framework makes them exceptionally stable to physical, chemical, and biological degradation compared to linear peptides of similar size. The cyclotides are also highly tolerant to sequence variability, aside from the conserved residues forming the cystine knot, and are orally bioavailable and able to cross cellular membranes to modulate intracellular protein–protein interactions (PPIs), both in vitro and in vivo. These unique properties make them ideal scaffolds for many biotechnological applications, including drug discovery. This review provides an overview of the properties of cyclotides and their potential for the development of novel peptide-based therapeutics. The selective disruption of PPIs still remains a very challenging task, as the interacting surfaces are relatively large and flat. The use of the cell-permeable highly constrained polypeptide molecular frameworks, such as the cyclotide scaffold, has shown great promise, as it provides unique pharmacological properties. The use of molecular techniques, such as epitope grafting, and molecular evolution have shown to be highly effective for the selection of bioactive cyclotides. However, despite successes in employing cyclotides to target PPIs, some of the challenges to move them into the clinic still remain. |
format | Online Article Text |
id | pubmed-6631875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66318752019-08-19 The Potential of the Cyclotide Scaffold for Drug Development Camarero, Julio A. Campbell, Maria Jose Biomedicines Review Cyclotides are a novel class of micro-proteins (≈30–40 residues long) with a unique topology containing a head-to-tail cyclized backbone structure further stabilized by three disulfide bonds that form a cystine knot. This unique molecular framework makes them exceptionally stable to physical, chemical, and biological degradation compared to linear peptides of similar size. The cyclotides are also highly tolerant to sequence variability, aside from the conserved residues forming the cystine knot, and are orally bioavailable and able to cross cellular membranes to modulate intracellular protein–protein interactions (PPIs), both in vitro and in vivo. These unique properties make them ideal scaffolds for many biotechnological applications, including drug discovery. This review provides an overview of the properties of cyclotides and their potential for the development of novel peptide-based therapeutics. The selective disruption of PPIs still remains a very challenging task, as the interacting surfaces are relatively large and flat. The use of the cell-permeable highly constrained polypeptide molecular frameworks, such as the cyclotide scaffold, has shown great promise, as it provides unique pharmacological properties. The use of molecular techniques, such as epitope grafting, and molecular evolution have shown to be highly effective for the selection of bioactive cyclotides. However, despite successes in employing cyclotides to target PPIs, some of the challenges to move them into the clinic still remain. MDPI 2019-04-19 /pmc/articles/PMC6631875/ /pubmed/31010257 http://dx.doi.org/10.3390/biomedicines7020031 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Camarero, Julio A. Campbell, Maria Jose The Potential of the Cyclotide Scaffold for Drug Development |
title | The Potential of the Cyclotide Scaffold for Drug Development |
title_full | The Potential of the Cyclotide Scaffold for Drug Development |
title_fullStr | The Potential of the Cyclotide Scaffold for Drug Development |
title_full_unstemmed | The Potential of the Cyclotide Scaffold for Drug Development |
title_short | The Potential of the Cyclotide Scaffold for Drug Development |
title_sort | potential of the cyclotide scaffold for drug development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631875/ https://www.ncbi.nlm.nih.gov/pubmed/31010257 http://dx.doi.org/10.3390/biomedicines7020031 |
work_keys_str_mv | AT camarerojulioa thepotentialofthecyclotidescaffoldfordrugdevelopment AT campbellmariajose thepotentialofthecyclotidescaffoldfordrugdevelopment AT camarerojulioa potentialofthecyclotidescaffoldfordrugdevelopment AT campbellmariajose potentialofthecyclotidescaffoldfordrugdevelopment |